In addition to our findings, recent reports also demonstrate that GAL-9/TIM-3 interactions support the maintenance of leukemia-initiating cells (LICs), promote immune evasion in AML models, and that GAL-9 is upregulated in AML patients who fail chemotherapy treatment53,70–73. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.